Rinvoq has been approved by the FDA for the treatment of moderate to severe Rheumatoid Arthritis. In Europe, Rinvoq is approved for moderate to severe Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis treatment, and for adults and adolescents 12 years and older with moderate to severe Atopic Dermatitis.